Skip to content

Clinical observation on the effect of Lingze tablet in the treatment of BPH patients in community hospitals in the real world

Clinical observation on the effect of Lingze tablet in the treatment of BPH patients in community hospitals in the real world

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003376
Enrollment
Unknown
Registered
2020-06-07
Start date
2020-06-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia

Interventions

Sponsors

Dongzhimen Hospital Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the diagnostic criteria of BPH; 2. Male patients aged 50-80 years; 3. Patients who voluntarily sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with BPH symptoms (such as diuretics, antihistamines or tricyclic antidepressants) were treated with other drugs with known efficacy within 4 weeks; 2. Patients with other previous urinary system diseases (prostatitis, urinary incontinence, urethral stricture or prostate cancer), or previous lower urinary tract surgery; 3. Patients with serious cardiovascular and cerebrovascular diseases, liver and kidney dysfunction and other serious primary diseases; 4. Allergic constitution and patients with severe drug allergy history; 5. Patients with mental diseases; 6. Patients who participated in other clinical studies 6 months before the study.

Design outcomes

Primary

MeasureTime frame
IPSS;B-mode ultrasonography;PSA;QOL;Urinary flow rate;

Countries

China

Contacts

Public ContactBin Wang

Beijing University of Traditional Chinese Medicine

2271766346@qq.com+86 13911103953

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026